IP Library Patent Application 12571465
Patent Application
App. No. 12/571,465

Contact Lens Care Solutions with a Low Molecular Weight Oligomer

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/571,465
Abstract

A contact lens care solution comprising: a cationic antimicrobial component having an average molecular weight (M NA ), and a cationic oligomer or nitrogen/amine oligomer having a number average molecular weight (M NO ) from 500 daltons to 15,000 daltons. The lens care solutions are used to clean and disinfect contact lenses, and in particular, soft, silicone hydrogel contact lenses.

Claims (18)

1 . A contact lens care solution comprising:

a cationic antimicrobial component having an average molecular weight (M NA ); and

a cationic oligomer or nitrogen/amine oligomer having a number average molecular weight (M NO ) from 500 daltons to 15,000 daltons, wherein the wherein the cationic oligomer or nitrogen/amine oligomer is present in the composition from 0.01 wt. % to 1.0 wt. %, and the composition comprises a ratio M NO :M NA from 5:1 to 1:5.

2 . The lens care solution of claim 1 , wherein the ratio M NO :M NA is from 3:1 to 1:3.

3 . The lens care solution of claim 1 , wherein the cationic antimicrobial component is poly(hexamethylene biguanide), which is present in the composition from 0.3 ppm to 2 ppm, or polyquaternium-1, which is present in the composition from 0.5 ppm to 15 ppm.

4 . The lens care solution of claim 1 , further comprising a comfort agent selected from the group consisting of dexpanthenol, hydroxypropyl guar, hyaluronic acid, hydroxypropylmethyl cellulose and the corresponding metal salts of each thereof.

5 . The lens care solution of claim 4 , wherein the comfort agent is hyaluronic acid.

6 . The lens care solution of claim 1 , wherein the cationic oligomer or nitrogen/amine oligomer is selected from the group consisting of polyvinylpyridine, polyvinylpyrrolidone, polyethyleneimine and a copolymer comprising polyvinylpyridine, polyvinylpyrrolidone or polyethyleneimine.

7 . The lens care solution of claim 1 , wherein the number average molecular weight of the cationic oligomer or nitrogen/amine oligomer is from 1500 daltons to 6000 daltons.

8 . The lens care solution of claim 6 , wherein the number average molecular weight of the cationic oligomer or nitrogen/amine oligomer is from 1500 daltons to 6000 daltons.

9 . The lens care solution of claim 6 , wherein the cationic antimicrobial component is poly(hexamethylene biguanide) and is present in the solution from 0.1 ppm to 2.0 ppm, and the hyaluronic acid and is present in the composition from 0.005 wt. % to 0.04 wt. %.

10 . A method of cleaning and disinfecting a contact lens, the method comprising instructing a person who uses contact lenses to soak the contact lens in the composition of claim 1 for at least 2 hours.

11 . The method of claim 10 , further comprising instructing the person to place the soaked contact lens on the eye without the need to rinse the soaked lens prior to placement on the eye.

12 . A contact lens care solution comprising:

a cationic antimicrobial component having an average molecular weight (M NA ); and

0.01 wt. % to 1.0 wt. % polyvinylpyrrolidone oligomer having a number average molecular weight (M NO ) from 500 daltons to 5,000 daltons, and the composition comprises a ratio M NO :M NA from 5:1 to 1:5.

13 . The lens care solution of claim 12 , wherein the ratio M NO :M NA is from 3:1 to 1:3.

14 . The lens care solution of claim 12 , wherein the cationic antimicrobial component is poly(hexamethylene biguanide), which is present in the composition from 0.3 ppm to 2 ppm, polyquaternium-1, which is present in the composition from 0.5 ppm to 15 ppm, or polyquaternium-42, which is present in the composition from 5 ppm to 60 ppm.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Sep 4, 2013
From: BAUSCH & LOMB INCORPORATED
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 031156/0508 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2013
From: CITIBANK N.A., AS ADMINISTRATIVE AGENT
To: WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.); BAUSCH & LOMB INCORPORATED; ISTA PHARMACEUTICALS
Reel/Frame 030995/0444 →
SECURITY AGREEMENT Recorded Aug 6, 2012
From: BAUSCH & LOMB INCORPORATED; EYEONICS, INC.
To: CITIBANK N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 028728/0645 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 19, 2009
From: LIU, X. MICHAEL; HEILER, DAVID J.
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 023543/0742 →